Background-Device implant pocket hematoma is a recognized complication after permanent pacemaker (PM) and implantable cardioverter-defibrillator (ICD) implantation. Pocket hematoma is associated with local discomfort, an increased risk of infection, and may require surgical intervention or lead to lengthier hospital stays. The purpose of the study was to identify the clinical factors associated with hematoma formation after PM or ICD device implantation. 
P ocket hematoma is a recognized common complication after placement of a permanent pacemaker (PM) or implantable cardioverter-defibrillator (ICD). Pocket hematoma is associated with local discomfort, an increased risk of infection, and may require surgical intervention or lead to lengthier hospital stays. Previous reports show an occurrence of pocket hematoma formation of 2% to 5%. 1,2 A variety of antiplatelet and anticoagulant drugs are routinely used in the treatment of cardiac patients. Antiplatelet therapy with aspirin (ASA) does not statistically increase the incidence of hematoma and is therefore thought to be an acceptable medication to continue perioperatively. Contrast studies have suggested that ASA combined with thienopyridine therapy (clopidogrel or ticlopidine) is associated with an increase the incidence of hematoma. 3, 4 Clopidogrel is a particularly potent antiplatelet drug. Its major mode of action is irreversible inhibition of ADP receptors, thus preventing platelet activation. 5 With increasing indications for clopidogrel in current practice, the relationship between antiplatelet therapy and hematoma is becoming more important than ever. We sought to further define the predictors of pocket hematoma in the present era of high-volume ICD implantation and hypothesized that the use of the potent antiplatelet agent clopidogrel and/or heparin would be strong predictors of this adverse outcome.
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Methods
Patient Characteristics
The subjects of this prospective, observational study were 935 consecutive patients at Beaumont Hospital who underwent implantation of a PM or an ICD over a period of 11 consecutive months beginning in January 2005. All patients undergoing device-related surgery, including new device implants, device generator changes, and lead revision were included in the analysis. Patients undergoing implantation of implantable looping event recorders were not enrolled. In cases in which 2 procedures were performed on the same hospitalization (nϭ19), only the outcome after the first procedure was included. All pacemakers and defibrillators were placed in a prepectoral pocket by experienced physicians (Ͼ100 implants, nϭ12). The majority of implants were performed solely by boardcertified clinical cardiac electrophysiologists, except for 4 implants by general cardiologists (0.4%) and 46 implants performed by cardiology fellows under the direct supervision of an attending electrophysiologist (4.5%). Anticoagulation therapy was prescribed by the attending cardiologist and/or implanting physician and was not altered for the purposes of this study. Physicians maintained usual practice patterns.
Study Protocol
Patients were prospectively enrolled into the study after successful completion of device implantation. Consent was obtained, and patients were then followed through hospital discharge. Data were obtained prospectively by a clinical nurse specialist who recorded information from patient interviews and the medical record. After the implant procedure, all patients were admitted to the hospital overnight for clinical monitoring. Patients were examined by the nurse clinician and by attending cardiologist the day after device implant. Patients with identified hematomas were followed daily while hospitalized and contacted by telephone after discharge. Late complications were identified by a patient being flagged if repeat hospital or emergency department visits occurred during the course of the study and by telephone follow-up interview.
A hematoma was defined to be present if there was palpable swelling with fluctuance over the device generator. Hematomas were categorized into 2 groups: Type 1 did not extend beyond 1 cm past the device margin, and a type 2 hematoma extended beyond 1 cm past the device margin and/or caused significant strain on incision site. Presence of a hematoma was determined by 1 of 2 experienced nurse clinicians. If possible hematoma was suspected but not certain, presence or absence of the hematoma was adjudicated by the physician investigators. Hematomas were treated with external compression, temporary discontinuation of anticoagulation if not contraindicated, and rarely with a course of antibiotic therapy if local cellulitis was suspected. With this approach, device pocket evacuation was only performed in 4 cases.
Statistical Analysis
Data were collected and entered prospectively in a computer database. The study hypothesis was tested by assessing the association of hematoma formation with prescription of anticoagulant and antiplatelet agents, including heparin, clopidogrel, and aspirin. To derive a list of other possible factors associated with hematoma formation, a range of clinical variables were also recorded prospectively and exploratory comparisons were performed. Categorical variables including presence of hematoma and the 3 clopidogrel subgroups ("off," "some," or "on") were summarized using frequencies and percentages and analyzed using the Pearson 2 where appropriate; otherwise, a Fisher exact test was used. As the continuous variables were skewed (ie, nonnormally distributed), they were summarized using medians and interquartile ranges (IQR) and analyzed using the nonparametric Kruskal-Wallis test. Age was analyzed using a Student t test because it was normally distributed. Multiple logistic regression analyses using backward elimination were completed to determine first predictors of hematoma. The least significant variable was dropped at each step until only those variables with PϽ0.05 remained. Included in the first step were primary prevention ICD, ASA use, any heparin use, and clopiogrel use. The concordance statistic (c), with its 95% confidence interval (CI) representing the area under the receiver operating characteristic curve, was also computed to assess the discriminatory ability of the fitted model. Odds ratios and corresponding 95% CI were also computed where appropriate. The type I error rate was adjusted to 0.05/6ϭ0.0083, 0.05/7ϭ0.0071, and 0.05/4ϭ0.0125, respectively, for multiple testing of the variables device implant indication, indications for clopidogrel use, and vascular access. Elsewhere, probability values less than ␣ of 0.05 (probability of type I error) were considered statistically significant. Statistical analysis was preformed using The SAS System for Windows version 9.2 (SAS Institute Inc, Cary, NC).
Results
A total of 935 patients were enrolled in the study. The clinical characteristics of the cohort are described in Table 1 . Five hundred sixty-three patients were prescribed aspirin, and 216 patients were prescribed clopidogrel at the time of implant. One hundred thirty-seven patients were maintained on clopidogrel throughout the perioperative period, and 38 discontinued its use 1 to 10 days before implant. One hundred twenty-six patients were receiving clopidogrel and aspirin in combination. Indications for clopidogrel therapy included 1 or more of the following: coronary artery disease (nϭ134), 92 of whom had recent stent placement, peripheral vascular disease (nϭ23), cerebrovascular disease (nϭ40), and/or other less common indications (nϭ25). Three hundred five patients were taking warfarin immediately before the procedure. The practice during the study period was to discontinue warfarin 3 to 4 days before device implant and then reinitiate it 0 to 2 days after the procedure. The median prothrombin time international normalized ratio among these patients at time of implant was 1.3 (IQR, 1.1 to 1.5). Sixteen patients (5% of those prescribed warfarin) had a therapeutic INR at the time of surgery (medianϭ2.2; IQR, 2.0 to 2.3). One hundred twenty-two patients received heparin (low-molecular-weight, 
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nϭ31, or intravenous, nϭ91). The most common indications for heparin use were the presence of a mechanical prosthetic heart valve or high risk for thromboembolism. Lowmolecular-weight heparin was held 12 hours before procedure and usually initiated 24 hours after implantation. Intravenous heparin was typically held 6 hours before the procedure and restarted 6 to 12 hours after implantation at the discretion of the implanting physician. Of the total population of 935 patients, 164 patients received no antiplatelet or anticoagulation before or after the device implant, and 283 received aspirin only. A pocket hematoma was documented in 89 of 935 patients. Only 6 patients had hematomas that extended Ͼ1 cm beyond the device edge, were tense, and threatened the integrity of the wound closure; therefore, both types of hematoma are grouped together for purposes of statistics. Of the 165 patients receiving no antiplatelet or anticoagulation therapy, only 7 patients (4.2%) had a hematoma. Among the 137 patients treated with ongoing clopidogrel therapy as monotherapy or in combination with other drugs, 25 (18.3%) had a pocket hematoma versus 64 of 798 patients (8.0%) not receiving clopidogrel within 14 days of surgery ( Figure 1 and Table 2 ). Among 38 patients chronically treated with clopidogrel but discontinued within 14 days (median 4 days) before implantation, 4 (10.5%) had a pocket hematoma (Figure 2) . Thus, the dosing of clopidogrel was directly related to the frequency of pocket hematoma (Pϭ0.0007). The frequency of hematoma for each combination drug regimen observed during the study is detailed in Table 3 .
The characteristics of patients with and without hematomas are listed in Table 4 . Pocket hematoma formation was not associated with age (mean differenceϭϪ2; CI, Ϫ4 to 0.9; Student t testϭϪ1.3; DFϭ933; Pϭ0.19), sex ( 2 ϭ1.57, 
24).
Multiple logistic regression analysis using backward elimination identified 3 variables as significant for development of device-related hematoma: device indicated for primary prevention of sudden cardiac death (a surrogate for primary ICD implant); clopidogrel use; and heparin use (Table 5) . Patients with device indication primary prevention of sudden cardiac death were 1.62 times as likely to have had devicerelated hematoma as those with "no device indication primary prevention of sudden cardiac death," after adjusting for heparin and clopidogrel use (95% CI, 1.03 to 2.54). Patients who were on heparin were 3.6 times as likely to have had device-related hematoma as those not on heparin, after adjusting for clopidogrel use and device indication primary prevention of sudden cardiac death (95% CI, 2.18 to 6.0). Patients on clopidogrel were 2.32 times as likely to have had device-related hematoma as those not on clopidogrel, after adjusting for device indication primary prevention of sudden cardiac death and heparin use (95% CI, 1.42 to 3.79). Using the logistic regression model an estimate of the risk of having an event (ie, device related hematoma) for each individual was calculated based on that individual's values of the covariates in the multivariate model (ie, indication, heparin use, and clopidogrel use). The c-statistic was 0.69 (0.63, 0.74) and represents the probability that a randomly selected person with a device related hematoma will have a higher predicted risk than that of a randomly selected patient without a device related hematoma.
Compared with patients without hematoma formation, patients who had a postoperative hematoma had a greater median hospital total length of stay (4 days [IQR, 1 to 9] with versus 2 days [IQR, 1 to 6] without hematoma; KruskalWallis testϭ8.5, DFϭ1, Pϭ0.004), which was mostly attributable to a greater length of stay after the procedure. Eightyseven of the patients with hematoma had excellent long-term outcomes, but the remaining 2 patients required subsequent lead and device removal because of the occurrence of infection after pocket hematoma. Patients with hematomas were more likely to require surgical intervention (5.6% versus 1.2%, Fisher exact test, Pϭ0.009), including hematoma evacuation (nϭ4), pocket and lead revision, or removal of infected device/lead systems (nϭ5), and have late complications (18% versus 1.9%, 2 ϭ63, DFϭ1, Pϭ0.0001). Late complications (nϭ16) included infection (nϭ9), recurrent hematoma (nϭ3), lead dislodgment (nϭ2), phrenic nerve stimulation (nϭ1), and deep venous thrombosis (nϭ1).
Discussion
Pocket hematoma after pacemaker or defibrillator implantation is a complication that can lead to local discomfort, infection, prolonged hospital stay, and/or need for lead and device revision. The use of antiplatelet drugs is increasing in prevalence, and indications for these drugs are broadening. Research has demonstrated that bleeding complications are significantly increased in patients undergoing revascularization surgery in the milieu of clopidogrel. 6 To date, the implications of ongoing clopidogrel therapy with implantation of pacemakers or defibrillators has not been adequately evaluated. By analyzing a large cohort of patients, we were able to assess the relationship between pocket hematoma and clopidogrel therapy.
The present study was a prospective evaluation in the modern era of antiplatelet drug use. Patients undergoing various types of device-related procedures including highenergy device implants were evaluated. This population is typical of a large tertiary care center with multiple implanters. To date, there is no other prospective trial following device patients on antiplatelet medication. The overall rate of pocket hematoma was 9%, which could be attributed to the high number of patients receiving intravenous heparin or maintained on clopidogrel during the course of the study. In patients on no anticoagulant or antiplatelet therapy, or those on simply aspirin, the overall rate of hematoma was Ͻ1%. The use of heparin or clopidogrel increased that risk Ͼ20-fold. Patients who had hematoma had longer hospital stays and were more likely to have late complications or require repeat surgical intervention. However, patients in whom clopidogrel had been held for 3 to 4 days before the procedure had a frequency of hematoma that approached baseline. This may be due to a critical number of platelets that regenerated during this brief window of drug withdrawal. No adverse cardiac events were observed during the period of clopidogrel discontinuation in those patients. Therefore, withdrawing clopidogrel therapy before implantation may improve the safety of the procedure assuming that its withdrawal is not contraindicated because of recent insertion of coronary or intravascular stents. However, the number of patients in this group was small, and larger studies should examine this question before clopidogrel withdrawal before device implantation is routinely recommended. The estimated rate of stent thrombosis associated with lack of thienopyridine treatment is high in the first 6 months after DES implant-presumably, this would outweigh the risk of pocket hematoma at least in the first few months after stent placement. Further studies would need to address the risk of short-term withdrawal in patients undergoing device implant versus the benefits of avoiding hematoma.
The present study demonstrated a trend toward decreased hematoma formation in patients undergoing a cephalic cutdown implant technique. A likely reason for this observation is that direct visualization and controlled lead placement into the vessel should minimize late back bleeding into the pocket. It is well documented that complications decrease as im- planter experience increases. 7, 8 All of our operators were high-volume implanters, and no significant difference of hematoma rate was observed among operators.
Prior Studies
Studies of device implant complications that were performed before the availability of clopidogrel commonly reported infections and lead-related problems. 9 The largest trials from this era document very low prevalence of pocket hematoma (1% to 3%). These older studies tended to be small and focused mostly on pacemaker implantation with limited numbers of defibrillators. 1, 10 More recent studies have evaluated bleeding complications retrospectively in surgical patients receiving heparin, ticlid/clopidogrel, and warfarin. 3, 4 Similarities among these trials include an increase in the rate of hematoma in patients on heparin (both intravenous and subcutaneous). As was observed in the present study, the exposure to heparin consistently appears to be associated with increased development of pocket hematoma, with a corresponding 20% to 24% increase in length of stay. 5, 11 Clopidogrel use in patients undergoing coronary artery bypass surgery was associated with a significantly higher risk of surgical reexploration and transfusion requirements compared with aspirin treatment alone. 4 The present study is the largest prospective trial assessing surgical morbidity in cardiac patients treated with clopidogrel and confirms the substantial bleeding risk associated with its use in this setting.
Limitations
All data were derived from a single institution. Therefore, we cannot exclude the possibility that there is an institutional bias. It is possible that patients with more comorbidities (and greater clopidogrel use) had longer hospitalization after device implant and hence were available for observation for a longer period of time, leading to an ascertainment bias. Post-hospital discharge ascertainment bias for posthospitalization complications could have occurred as well. The study was designed as an unblended, prospective, observational trial. Thus, investigator bias during data collection and adjudication cannot be excluded. A randomized, controlled trial comparing ongoing clopidogrel versus drug withdrawal before device implant would be ideal to confirm this study's findings but may never be feasible because of the dangers of stopping clopidogrel after implantation of drug eluting stents and increasing indications for the long-term use of clopidogrel in coronary artery disease patients.
Clinical Implications
The occurrence of device pocket hematoma can be an inconvenience with associated pain and prolonged recovery for the patient, but it can also lead to dangerous outcomes such as wound dehiscence and pocket infection. Greater operator experience and meticulous surgical technique always improves patient outcome as well as choice of surgical approach (eg, cephalic cutdown). Withdrawal of clopidogrel may not be possible in patients who have received implantation of drug-eluting coronary stents; each case should be carefully assessed regarding the risk of clopidogrel therapy versus the risk of its withdrawal. Opportunities may exist for safely withholding intravenous heparin. Many operators are now performing device implants and invasive electrophysiological procedures on full-dose warfarin, and initial outcomes from clinical series are very favorable. 12, 13 Alternatively, fibrin sealant has been proposed as a useful agent to reduce risk of hematoma. 14 In any case, aggressive management with compression will minimize the risk of wound dehiscence. It is advisable only in the rare cases in which closure line integrity is threatened to surgically evacuate a hematoma, because opening the pocket at that juncture greatly increases the subsequent risk of infection.
Conclusions
Pocket hematoma is an infrequent complication of pacemaker and defibrillator implantation in patients on aspirin. Hematomas occur more frequently in patients receiving ICDs than PMs. Clopidogrel and intravenous heparin are independent predictors of pocket hematoma. The risk of hematoma formation is similar with either therapy. The amount of clopidogrel is directly related to the frequency of pocket hematoma. Pocket hematoma leads to increased length of hospital stay and increased late complications or surgical intervention. By withholding clopidogrel for 4 days before surgery, the excess risk of bleeding complications is decreased.
